- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01983241
Efficacité et innocuité de l'inhibiteur de l'alpha1-protéinase (humain), processus modifié (Alpha-1 MP) chez les sujets atteints d'emphysème pulmonaire dû à un déficit en alpha1 antitrypsine (AATD) (SPARTA)
Une étude randomisée, en double aveugle et contrôlée par placebo pour évaluer l'efficacité et l'innocuité de schémas posologiques à deux doses (60 mg/kg et 120 mg/kg) d'inhibiteur de la protéinase alpha1 intraveineuse hebdomadaire (humain) chez des sujets atteints d'emphysème pulmonaire dû à un déficit en alpha1 antitrypsine
This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses to be tested are 60 mg/kg and 120 mg/kg administered weekly by IV infusion for 156 weeks. The study consists of an optional pre-screening phase, Screening Phase, a 156-week Treatment Phase, and an End of Study Visit at Week 160.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Homburg Saar, Allemagne, 66421
- Grifols Investigative Site
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Allemagne, 69126
- Grifols Investigative Site
-
-
Hesse
-
Marburg, Hesse, Allemagne, 35043
- Grifols Investigative Site
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Allemagne, 45239
- Grifols Investigative Site
-
-
-
-
Buenos Aires
-
Vicente López, Buenos Aires, Argentine, B1602DOH
- Grifols Investigative Site
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentine, 5000
- Grifols Investigative Site
-
-
-
-
New South Wales
-
Sydney, New South Wales, Australie, 2010
- Grifols Investigative Site
-
-
Queensland
-
Chermside, Queensland, Australie, 4032
- Grifols Investigative Site
-
-
South Australia
-
Adelaide, South Australia, Australie, 5000
- Grifols Investigative Site
-
-
Victoria
-
Fitzroy, Victoria, Australie, 3065
- Grifols Investigative Site
-
-
Western Australia
-
Nedlands, Western Australia, Australie, 6009
- Grifols Investigative Site
-
-
-
-
São Paulo
-
Santo André, São Paulo, Brésil, 09060-650
- Grifols Investigative Site
-
São Paulo, São Paulo, Brésil, 04023-061
- Grifols Investigative Site
-
São Paulo, São Paulo, Brésil, 05403-000
- Grifols Investigative Site
-
-
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Grifols Investigative Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H3A8
- Grifols Investigative Site
-
-
Ontario
-
Toronto, Ontario, Canada, M5T3A11
- Grifols Investigative Site
-
-
-
-
-
Arhus C, Danemark, 8000
- Grifols Investigative Site
-
Hellerup, Danemark, 2900
- Grifols Investigative Site
-
-
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Espagne, 33011
- Grifols Investigative Site
-
-
Vizcaya
-
Barakaldo, Vizcaya, Espagne, 48903
- Grifols Investigative Site
-
-
-
-
-
Tallinn, Estonie, 13419
- Grifols Investigative Site
-
Tartu, Estonie, 51014
- Grifols Investigative Site
-
-
-
-
-
Turku, Finlande, 20520
- Grifols Investigative Site
-
-
-
-
Gironde
-
Pessac, Gironde, France, 33604
- Grifols Investigative Site
-
-
Rhone
-
Bron, Rhone, France, 69500
- Grifols Investigative Site
-
-
-
-
-
Chisinau, Moldavie, 2025
- Grifols Investigative Site
-
-
-
-
-
Auckland, Nouvelle-Zélande, 1051
- Grifols Investigative Site
-
Christchurch, Nouvelle-Zélande, 8013
- Grifols Investigative Site
-
Hamilton, Nouvelle-Zélande, 3240
- Grifols Investigative Site
-
-
-
-
-
Krakow, Pologne, 31-066
- Grifols Investigative Site
-
Warsaw, Pologne, 01-138
- Grifols Investigative Site
-
-
-
-
-
Oradea, Roumanie, 410176
- Grifols Investigative Site
-
Timișoara, Roumanie, 300312
- Grifols Investigative Site
-
-
-
-
-
Barnaul, Russie, 656038
- Grifols Investigative Site
-
Moscow, Russie, 105077
- Grifols Investigative Site
-
Yaroslavl, Russie, 150003
- Grifols Investigative Site
-
-
-
-
-
Gothenburg, Suède, 41345
- Grifols Investigative Site
-
Linköping, Suède, 587 58
- Grifols Investigative Site
-
Malmö, Suède, 20502
- Grifols Investigative Site
-
Stockholm, Suède, 11361
- Grifols Investigative Site
-
Uppsala, Suède, 752 37
- Grifols Investigative Site
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85013
- Grifols Investigative Site
-
-
Florida
-
Gainesville, Florida, États-Unis, 32610
- Grifols Investigative Site
-
Leesburg, Florida, États-Unis, 34748
- Grifols Investigative Site
-
Miami, Florida, États-Unis, 33136
- Grifols Investigative Site
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63110
- Grifols Investigative Site
-
-
North Carolina
-
Wilmington, North Carolina, États-Unis, 28401
- Grifols Investigative Site
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Grifols Investigative Site
-
-
Pennsylvania
-
Hershey, Pennsylvania, États-Unis, 17033
- Grifols Investigative Site
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Grifols Investigative Site
-
-
Texas
-
Tyler, Texas, États-Unis, 75708
- Grifols Investigative Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Have a documented total alpha1-PI serum level < 11 µM.
- Have a diagnosis of congenital AATD with an allelic combination of ZZ, SZ, Z(null), (null)(null), S(null), or "at-risk" alleles.
- At the Screening (Week -3) Visit, have a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 30% and < 80% of predicted and FEV1/forced vital capacity (FVC) < 70% (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II or III).
- Have a carbon monoxide diffusing capacity (DLCO) ≤ 60% of predicted (corrected for HgB) within the past 2 years OR evidence of pulmonary emphysema on CT scan within the past 2 years per the Investigator's judgment.
- Have clinical evidence of pulmonary emphysema per the Investigator's judgment.
Exclusion Criteria:
- Has received alpha1-PI augmentation therapy for more than 1 month within the six months prior to the Screening Visit.
- Has received alpha1-PI augmentation therapy within one month of the Screening Visit.
- Has had a chronic obstructive pulmonary disease (COPD) exacerbation within the 5 weeks prior to the Screening Visit or during the Screening Phase.
- Unable to physically (e.g., unable to fit inside the CT scanner) or mentally (e.g., claustrophobic) undergo a CT scan.
- History of lung or liver transplant.
- Any lung surgery during the past 2 years (excluding lung biopsy).
- On the waiting list for lung surgery, including lung transplant.
- Smoking during the past 12 months or a positive urine cotinine test at screening that is due to smoking. Maybe on Nicotine replacement, including vapor cigarettes.
- History of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI preparation or other blood product(s).
- Use of systemic steroids above a stable dose equivalent to 5 mg/day prednisone (i.e., 10 mg every 2 days) within the 5 weeks prior to the Screening Visit (inhaled steroids are not considered systemic steroids) or during the Screening Phase.
- Use of systemic or aerosolized antibiotics for a COPD exacerbation within the 5 weeks prior to the Screening Visit or during the Screening Phase.
- Known selective or severe Immunoglobulin A (IgA) deficiency.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Alpha-1 MP 60 mg/kg
Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks |
Autres noms:
|
|
Expérimental: Alpha-1 MP 120 mg/kg
Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks |
Autres noms:
|
|
Comparateur placebo: Placebo
0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks |
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from Baseline in Whole lung PD15 (15th percentile point)
Délai: Week -3 (baseline measure), Week 52, Week 104, Week 130, Week 156
|
Whole lung PD15 measured by CT scan |
Week -3 (baseline measure), Week 52, Week 104, Week 130, Week 156
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Adverse Events (AEs)
Délai: Week -3 through Week 160
|
Monitoring of AEs |
Week -3 through Week 160
|
|
Serious Adverse Events (SAEs)
Délai: Week -3 through Week 160
|
Monitoring of SAEs |
Week -3 through Week 160
|
|
Discontinuations from the study due to AEs
Délai: Week -3 through Week 160
|
Monitoring of discontinuations due to AEs |
Week -3 through Week 160
|
|
Severe COPD Exacerbations
Délai: Week -3 through Week 160
|
Severe COPD exacerbations as defined by American Thoracic Society/European Respiratory Society (ATS/ERS) criteria (i.e., COPD exacerbations requiring hospitalization) |
Week -3 through Week 160
|
|
Change from Baseline in PD15 of the basal lung region
Délai: Week -3 (baseline measure), Week 52, Week 104, Week 130, Week 156
|
PD15 of the basal lung region measure by CT scan |
Week -3 (baseline measure), Week 52, Week 104, Week 130, Week 156
|
|
Change from baseline in carbon monoxide diffusing capacity (DLco)
Délai: Weeks 26, 52, 78, 104, 130 and 156
|
DLco performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines |
Weeks 26, 52, 78, 104, 130 and 156
|
|
Changes from baseline in forced expiratory volume in 1 second (FEV1)
Délai: Weeks 26, 52, 78, 104, 130 and 156
|
FEV1 performed according to ATS/ERS guidelines |
Weeks 26, 52, 78, 104, 130 and 156
|
|
Change from baseline in Saint George's Respiratory Questionnaire: Minimum value = 0, maximum value = 100, higher scores indicate worse condition
Délai: Weeks 26, 52, 78, 104, 130 and 156
|
Health-related quality of life assessment tool |
Weeks 26, 52, 78, 104, 130 and 156
|
|
Change from baseline in the EuroQoL (Quality of Life)- 5 Dimension- 5 Level (EQ-5D-5L): Minimum value (for each one of the 5 levels) = 1, maximum value (for each one of the 5 levels) = 5, higher scores indicate worse condition
Délai: Weeks 26, 52, 78, 104, 130 and 156
|
Heath-related quality of life assessment tool |
Weeks 26, 52, 78, 104, 130 and 156
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Maladie chronique
- Attributs de la maladie
- Maladies génétiques, innées
- Maladies des voies respiratoires
- Maladies du système digestif
- Maladies pulmonaires
- Maladies pulmonaires obstructives
- Maladies du foie
- Emphysème sous-cutané
- Emphysème
- Maladie pulmonaire obstructive chronique
- Maladies et anomalies congénitales, héréditaires et néonatales
- Conditions pathologiques, signes et symptômes
- Emphysème pulmonaire
- carence en alpha 1-assine
- Thérapeutique
- Voies d'administration du médicament
- Pharmacothérapie
- Produits chimiques inorganiques
- Composés de chlore
- Composés de sodium
- Chlorures
- Acide chlorhydrique
- Injections
- Chlorure de sodium
- Récepteur Mp alpha1
Autres numéros d'identification d'étude
- GTi1201
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .